Rigel Pharmaceuticals CEO and leadership

Mr. George B. Kauffman is a Chairman Chief Executive Officer;Chief Investment Officier at RIGEL PHARMACEUTICALS INC and is based in United States.

Raul R. Rodriguez is the president and chief executive officer of [Rigel Pharmaceuticals](https://www.crunchbase.com/organization/rigel-pharmaceuticals), a company that develops small-molecule drugs for the treatment of autoimmune diseases, cancer, and metabolic diseases. He was previously the chief operating officer of Ontogeny. Before he joined Ontogeny, he served as an executive officer at Sense Technologies and a director at Scios. He also held various positions at Searle Pharmaceuticals. Rodriguez holds an MBA from Stanford University and an MPH from the University of Illinois.

David Santos was appointed Executive Vice President and Chief Commercial Offcer in August 2020. Mr. Santos joined Rigel from Jazz Pharmaceuticals, where he held the role of Hematology/Oncology Business Unit Head, responsible for leading US commercialization of the oncology portfolio. During his tenure at Jazz, he successfully grew the business unit through three launches to eventually have four promoted products in the leukemia, transplant and lung cancer markets. Prior to joining Jazz, Mr. Santos served as Vice President of Sales and Marketing for Medivation (now Pfizer), responsible for commercializing Xtandi@ for metastatic prostate cancer, and Vice President, Kinase Inhibitor Franchise for Onyx (now Amgen), responsible for leading sales and marketing efforts with Nexavar@ and Stivarga@. Before his work at Onyx, Mr. Santos served for nearly 9 years in roles of increasing responsibility at Genentech, Inc. (now a member of the Roche Group), where he launched and held key commercial leadership roles on several successful brands, including Avastin@, Herceptin@ and Tarceva@. Mr. Santos also held marketing and sales roles at Lilly Oncology and Bristol-Myers Squibb, where he started his pharmaceutical sales career. He received his BS in Chemistry from St. Louis University.

Mr. Schorno oversees Adaptive’s financial infrastructure, investor relations, human resources, and facilities management. He enjoyed 13 years of distinguished leadership positions at Genomic Health spanning financial, laboratory, and business operations. Prior to his most recent three-year tenure as CFO, Mr. Schorno managed the launch and operations of Genomic Health’s clinical laboratory and oversaw financial affairs on a global basis. Before joining Genomic Health, Dean founded and led a CPA and consulting firm. Dean holds a Bachelor of Science degree in Business Administration, from the University of California, Berkeley, and is a Certified Public Accountant.

- Chief Medical Officer/Executive Vice President at Aridis

- Leadership and partnership with CEO, CFO through Aridis IPO on Aug 24, 2018 (NASDAQ ticker : ARDS)

- Vice President of Clinical Development at BioMarin (2012-2016). Built and managed a Clinical Science Department with up to 15 Medical Directors running a rare disease drug development pipeline of up to 7 molecules and 22 clinical trials, leading to several drug approvals.

- Led elosulfase alpha (VIMIZIM) through rare disease phase 3, BLA/EU MA filing and FDA Advisory Committee preparation (Nov 2013), leading to VIMIZIM approval in the US (14 Feb 2014), EU (April 2014) and multiple countries worldwide. Vimizim is now BioMarin’s top commercial product and BioMarin’s Market Cap increased from about 6 Billion $ to approximately 15 Billion $ in 2016.

- Genentech tenure 2001-2012 in positions of increasing responsibility. Global Development Leader for Ocrelizumab and Rituximab overseeing multiple indications including Rheumatoid Arthritis, Systemic Lupus, Lupus Nephritis, Multiple Sclerosis, GI, ANCA-associated vasculitis, etc..

- Led Genentech’s development program for Ocrelizumab in RA from pre-IND through phase 1, phase 2 and 4 phase 3 trials (WD senior author on 5 Ocrelizumab publications). Ocrelizumab approved in 04/17 in PPMS and RRMS with 3-5 Billion dollars annual revenue estimate.

- Medical Doctor with Clinical Board Certification in Dermatology and Allergy/Immunolgy

- Research Scientist (1998-2001) at The Scripps Research Institute, Department of Immunolgy, La Jolla, California (T cell Bcell immunology, immuno-oncology)

- Over 40 publications, with high impact papers in New England Journal of Medicine, Journal Clinical Investigation, Journal of Immunology, Proc Natl Acad Sciences, Science Translational Medicine, Arthritis&Rheumatism, and others.

Raul R. Rodriguez is the president and chief executive officer of [Rigel Pharmaceuticals](https://www.crunchbase.com/organization/rigel-pharmaceuticals), a company that develops small-molecule drugs for the treatment of autoimmune diseases, cancer, and metabolic diseases. He was previously the chief operating officer of Ontogeny. Before he joined Ontogeny, he served as an executive officer at Sense Technologies and a director at Scios. He also held various positions at Searle Pharmaceuticals. Rodriguez holds an MBA from Stanford University and an MPH from the University of Illinois.